A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2- hydroxypropyl)methacrylamide (HPMA) copolymer carrier

European Journal of Cancer

Volumn 35, Issue 3, 1999, Pages 459-466

  St'astny M ^a   Strohalm, J ^b   Plocova D ^b   Ulbrich, K ^b   Rihova B ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Antibody targeting; Chemosensitisers; Doxorubicin; HPMA; Multidrug resistance; P glycoprotein; Polymeric prodrugs

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; COPOLYMER; CYCLOSPORIN A; CYCLOSPORIN D; CYCLOSPORIN G; CYTOSTATIC AGENT; DOXORUBICIN; DRUG CARRIER; GLYCOPROTEIN P; THYMOCYTE ANTIBODY; TRANSFERRIN;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG TARGETING; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOSPORINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOTOXINS; METHACRYLATES; MICE; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0033105569     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00373-6     Document Type: Article

References (38)

1. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 58:1989;137-171.
2. Gottesman M.M. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 53:1993;747-754.
3. Froidevaux S., Loor F. Myeloid and lymphoid cell alterations in normal mice exposed to chemotherapy with doxorubicin and/or the multidrug-resistance reversing agent SDZ PSC 833. Int J Cancer. 59:1994;133-140.
4. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. PNAS USA. 84:1987;265-269.
5. Duncan R. Polymer-drug conjugates: potential for improved chemotherapy. Anti-Cancer Drugs. 3:1992;175-210.
6. Kopeček J. Reactive copolymers of N-(2-hydroxypropyl) methacrylamide with N-methacryloylated derivatives of L-leucine and L-phenylalanine. Makromol Chem. 178:1977;2169-2183.
7. 125I] daunomycin. J Control Rel. 10:1989;37-49.
8. Cassidy J, Vasey P, Kaye SB, Duncan R. A phase I clinical trial of PK1: a novel drug targeting system in human cancers. Proceedings of the 2nd International Symposium on Polymer Therapeutics Kumamoto, Japan, 18-20 April, 1997, p. 18.
9. Říhová B. Antibody-targeted polymer-bound drugs. Folia Microbiol. 40:1995;367-384.
10. Kerr DJ, Seymour LW, Boivin P, et al. Phase I clinical trial of HPMA copolymers bearing doxorubicin and galactosamine. Proceedings of the 3rd International Symposium on Polymer Therapeutics, London, 7-9 January, 1988, p. 23.
11. Rejmanová P., Kopeček J., Duncan R., Lloyd J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in HPMA copolymers. Biomaterials. 6:1985;45-48.
12. Duncan R., Kopečková P., Strohalm J., Hume I.C., Lloyd J.B., Kopeček J. Anticancer agents coupled to HPMA-copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukemia. Br J Cancer. 57:1988;147-156.
13. Říhová B., Kopečková P., Strohalm J., Rossmann P., Větvička V., Kopeček J. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin Immunol Immunopathol. 46:1988;100-114.
14. Říhová B., Bilej M., Větvička V., et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials. 10:1989;335-342.
15. Seymour L.W., Ulbrich K., Strohalm J., Kopeček J., Duncan R. The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol. 39:1990;1125-1131.
16. Št'astný M., Říhová B., Strohalm J., Ulbrich K. Comparison of binding kinetics of antibody-targeted N-(2-hydroxypropyl)methacrylamide (HPMA)-bound doxorubicin in vitro and in vivo. J Control Rel. 42:1996;229-236.
17. Levey R.H., Medawar P.B. Some experiments on the action of antilymphoid antisera. Ann NY Acad Sci. 120:1966;164-177.
18. Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:1979;55-63.
19. Witherspoon S.M., Emerson D.L., Kerr B.M. Flow cytometric analyses of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res. 2:1996;7-12.
20. Duncan R., Kopečková P., Strohalm J., Hume I.C., Lloyd J.B., Kopeček J. Anticancer agents coupled to HPMA-copolymers. Evaluation of daunomycin and puromycin conjugates in vitro. Br J Cancer. 55:1987;165-174.
21. Rejmanová P., Pohl J., Baudyš M., Kostka V., Kopeček J. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol Chem. 184:1983;2009-2020.
22. Duncan R., Seymour L.W., O'Hare K.B., Ulbrich K. Preclinical evaluation of polymer-bound DOX. J Control Rel. 19:1992;331-346.
23. Říhová B., Kopeček J. Biological properties of targetable poly[N-(2-hydroxypropyl)methacrylamide]-antibody conjugates. J Control Rel. 2:1985;289-310.
24. Šubr V., Strohalm J., Ulbrich K., Duncan R., Hume I.C. Polymers containing enzymatically degradable bonds. XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymer drug carriers in vitro and antitumour activity measured in vivo. J Control Rel. 18:1992;123-132.
25. Strohalm J., Kopeček J. Poly[N-(2-hydroxypropyl)methacrylamide]. IV. Heterogeneous polymerization. Angew Makromol Chem. 70:1978;109-118.
26. Ulbrich K., Šubr V., Seymour L.W., Duncan R. Novel biodegradable hydrogels prepared using the divinylic crosslinking agent N,O-dimethacryloylhydroxylamine. 1. Synthesis and characterization of rates of gel degradation, and rate of release of model drugs, in vitro and in vivo. J Control Rel. 24:1993;181-190.
27. Ulbrich K., Šubr V., Podpérová P., Burešová M. Synthesis of novel hydrolytically degradable hydrogels for controlled drug release. J Control Rel. 34:1995;155-165.
28. Ling Y.H., Priebe W., Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res. 53:1993;1845-1852.
29. Omelyanenko V., Gentry C., Kopečková P., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer. 75:1998;600-608.
30. Minko T, Kopećková P, Pozharov V, Kopeček J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Rel (in press).
31. Suzuki H., Zelphati O., Hildebrand G., Leserman L. CD4 and CD7 molecules as targets for drug delivery from antibody bearing liposomes. Exp Cell Res. 193:1991;112-119.
32. Van Oosterhout Y.V., van den Herik-Oudijk I.E., Wessels H.M., de Witte T., van de Winkel J.G., Preijers F.W. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res. 54:1994;3527-3532.
33. Ostergaard H.L., Trowbridge I.S. Coclustering CD45 with CD4 or CD8 alters phosphorylation and kinase activity of p56lck. J Exp Med. 172:1990;347-350.
34. Venne A., Li S., Mandeville R., Kabanov A., Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport and subcellular distribution of doxorubicin in multi-drug resistant cells. Cancer Res. 56:1996;3626-3629.
35. Alakhov V.Y., Moskaleva E.U., Batrakova E.V., Kabanov A. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem. 7:1996;209-216.
36. Št'astný M., Ulbrich K., Strohalm J., Rossmann P., Říhová B. Abnormal differentiation of thymocytes induced by free cyclosporin is avoided when cyclosporin bound to HPMA copolymer is used. Transplantation. 63:1997;1818-1827.
37. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and antitumor agent SMANCS. Cancer Res. 46:1986;6387-6392.
38. Maeda H, Miyamoto Y. SMANCS approach - oily formulations of protein drugs for arterial injection and oral administration. In de Boer AG, ed. Drug Absorption Enhancement - Concepts, Possibilities, Limitations and Trends. Chur, Harwood Academic Publishers, 1994, 221-247.